Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review.

Autor:	Ortiz JF; Neurology, Larkin Community Hospital, Miami, USA., Parwani J; Neurology, Lokmanya Tilak Municipal Medical College, Mumbai, IND., Millhouse PW; General Practice, Drexel University College of Medicine, Philadelphia, USA., Eissa-Garcés A; Neurology, Universidad San Francisco de Quito, Quito, ECU., Hassen G; Medicine and Surgery, University of Parma, Parma, ITA.; Progressive Care Unit, Mercy Medical Center, Baltimore, USA., Cuenca VD; Medicine, Universidad San Francisco de Quito, Quito, ECU., Alzamora IM; Neurology, Universidad San Francisco de Quito, Quito, ECU., Khurana M; Public Health, University of California Berkeley, Berkeley, USA., Herrera-Bucheli D; Medicine, Universidad Internacional del Ecuador, Quito, ECU., Altamimi A; Emergency Medicine, Amiri Hospital, Kuwait City, KWT., Atoot A; Internal Medicine, Palisades Medical Center, North Bergen, USA., Cueva W; Neurology, Larkin Community Hospital, Miami, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Nov 08; Vol. 13 (11), pp. e19358. Date of Electronic Publication: 2021 Nov 08 (Print Publication: 2021).
DOI:	10.7759/cureus.19358
Abstrakt:	Fabry disease (FD) is an X-linked disorder involving multiple organs. Stroke is a serious and frequent complication of FD. Cryptogenic stroke is a common presentation of FD, especially in the young population. The etiology of cryptogenic stroke is highly variable and difficult to assess, frequently leaving patients without a primary diagnosis. We conducted a systematic review to investigate the pooled prevalence of FD among patients with cryptogenic stroke, or patients with FD in whom a stroke was the presenting condition. English-language studies involving humans published in the last 20 years were included in this systematic review. FD was more common in male patients and tended to present at an earlier age. The frequency of hemorrhagic and ischemic strokes in this population was similar to that in the general population. There was a high rate of stroke recurrence in the study sample, even among patients undergoing enzyme replacement therapy. We conclude that screening for FD in patients with cryptogenic stroke is low yield and not cost-effective. However, it may be worthwhile to screen for FD among patients with recurrent strokes. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Ortiz et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu